Streetbeat News

Revenues

OLN

Olin Corporation (NYSE:OLN) was analyzed by 11 analysts, showing diverse opinions. The average 12-month price target is $52.64, with a high of $66.00 and a low of $38.00, marking a 10.95% decrease in the average target. Analyst actions include both upgrades and downgrades, with ratings ranging from 'Overweight' to 'Underweight'. Olin's financials show a -28.01% revenue decline over 3 months, a high net margin of 6.23%, an ROE of 4.37%, an ROA of 1.32%, and a healthy debt-to-equity ratio of 1.34. The majority of Olin's revenue comes from the United States, with its largest segment being Chlor alkali products and Vinyls.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 6:00 pm

NVO

Novo Nordisk's CEO anticipates a substantial increase in WEGOVY volumes in 2024. This expectation is based on the company's confidence in the product's market demand and potential growth. WEGOVY is a medication designed for weight management, and its increased volumes could signal a positive outlook for Novo Nordisk's revenue and market share in the weight management sector.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 5:54 pm

QCOM

Qualcomm's CEO has announced that the company is ahead of its revenue targets in the automotive sector. This positive development indicates that Qualcomm is making significant strides in expanding its business beyond its traditional stronghold in smartphone chips.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 5:50 pm

VRTX

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) has received approval from the Saudi Food and Drug Authority (SFDA) for CASGEVY, a CRISPR/Cas9 gene-edited therapy for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). This marks the first SFDA Breakthrough Designation and approval through this pathway, as well as Vertex's first regulatory approval in Saudi Arabia. Vertex is working to expand access to CASGEVY in Saudi Arabia by qualifying additional hospitals as Authorized Treatment Centers and securing hospital formulary listings for reimbursement.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 5:44 pm

FXI

ILMN

An executive from Illumina has indicated that the company's business operations in China are expected to face challenges throughout 2024, according to Reuters.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 5:35 pm

USO

The U.S. Energy Information Administration forecasts that OPEC+ will increase crude oil production by 700,000 barrels per day in 2025 as current output cuts expire, according to Reuters.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 5:31 pm

SRPT

Sarepta Therapeutics' stock is trading higher following the announcement of their expected preliminary net product revenues for Q4.

Portfolio Pulse from Benzinga Newsdesk

January 09, 2024 | 5:21 pm

ALK

BA

Boeing Co (BA) is under scrutiny after a door plug dislodged from an Alaska Air Group (ALK)-operated 737 MAX 9, leading to the grounding of some jets by the FAA. Analysts from Goldman Sachs, Bank of America, RBC Capital Markets, and JPMorgan commented on the potential impact on Boeing's reputation and operations, maintaining their ratings but noting the reputational and potential financial risks. The incident could also affect Boeing's resumption of deliveries to China, although Chinese carriers do not currently operate MAX 9s.

Portfolio Pulse from Surbhi Jain

January 09, 2024 | 5:17 pm

DIS

SONY

Zee Entertainment Enterprises Ltd. missed a $200 million payment to Walt Disney Co's India unit for cricket TV rights, amid financial challenges and uncertainty over its merger with Sony Group Corp. The missed payment raises concerns about Zee's cash conservation and potential legal issues, while Disney seeks explanations. Zee's stock struggles as it relies on cricket rights to boost viewership and advertising in cricket-loving India. Disney's stock dipped 1.08% to $90.56.

Portfolio Pulse from Shivani Kumaresan

January 09, 2024 | 5:02 pm

AXNX

Five analysts have provided ratings on Axonics (NASDAQ:AXNX) with diverse perspectives ranging from bullish to bearish. Over the last three months, there have been 2 bullish and 3 somewhat bullish ratings, with no changes in the past 30 days. The average 12-month price target is $70.0, with a high of $75.00 and a low of $63.00, marking a decrease from the previous average of $75.25. Analysts from Truist Securities, Piper Sandler, Morgan Stanley, Needham, and Leerink Partners have adjusted their price targets and ratings, reflecting their views on the company's performance and market conditions. Axonics, a medical technology company, has shown a revenue growth of 32.27% as of September 30, 2023, and has a market capitalization below the industry average. It also boasts a net margin of 4.22%, ROE of 0.65%, ROA of 0.6%, and a debt-to-equity ratio of 0.0.

Portfolio Pulse from Benzinga Insights

January 09, 2024 | 5:01 pm